{"slug":"policy","tag":"policy","variants":["policy"],"description":"No description yet","count":5,"kinds":{"person":2,"term":3},"related":[{"slug":"clinician-scientist","tag":"clinician-scientist","shared":1},{"slug":"evidence","tag":"evidence","shared":1},{"slug":"exercise","tag":"exercise","shared":1},{"slug":"global","tag":"global","shared":1},{"slug":"hta","tag":"hta","shared":1},{"slug":"leadership","tag":"leadership","shared":1}],"records":[{"id":"jonathan-benger","kind":"person","name":"Jonathan Benger","route":"/people/jonathan-benger/","tldr":"Emergency physician who became Chief Executive of NICE, the body that appraises new cancer medicines and issues clinical guidance for the NHS, in December 2025."},{"id":"christopher-booth","kind":"person","name":"Christopher M. Booth","route":"/people/christopher-booth/","tldr":"Oncologist who co-led CHALLENGE and founded Common Sense Oncology to refocus trials on outcomes that matter to patients."},{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/","tldr":"New cancer drugs commonly launch above $150,000-$250,000 per year in the US, with prices set without reference to benefit and hidden behind rebates; other countries negotiate or assess cost-effectiveness. Pricing policy determines who gets treated."},{"id":"oncology-workforce","kind":"term","name":"Oncology workforce","route":"/terms/oncology-workforce/","tldr":"There are not enough oncologists, radiation therapists, pathologists, oncology nurses and pharmacists for the growing number of patients, in rich countries and especially in poor ones; burnout, geography and training pipelines shape who receives care."},{"id":"who-essential-medicines","kind":"term","name":"WHO Essential Medicines List for cancer","route":"/terms/who-essential-medicines/","tldr":"The World Health Organization's list of medicines every health system should provide, which now includes about 60 cancer drugs from cyclophosphamide and cisplatin to trastuzumab, imatinib and PD-1 inhibitors, guiding procurement and pricing in lower-income countries."}]}